Skip to main content

Tripos s Revenues Slide 16 Percent, Earnings Increase in Q2

NEW YORK, July 28 (GenomeWeb News) - Tripos yesterday reported a drop in revenues amidst increased earnings for the second quarter of 2005.

 

Tripos' revenues were $13.4 million, down 16 percent from last year's $15.9 million during the same period. This decrease was "primarily due to the anticipated decline for the current stage of our Pfizer chemical file enrichment contract," said president and CEO John McAlister in a statement.

 

Research and development costs fell to $2 million, down from $2.5 million during the year-ago period.

 

Net income for the quarter was $1.7 million, or $.17 per share, up from $156,000, or $.02 per share, during last year's second quarter. Most of these earnings came from an income tax benefit of nearly $2 million.

 

As of June 30, Tripos had $6.2 million in cash and cash equivalents.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.